Phaseline

Companies › Vega Therapeutics

Vega Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Hematology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VGA039
Von Willebrand Factor (VWF) mimetic or modulator
–Phase 3Von Willebrand Disease (VWD); Von Willebrand DiseasesOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07115004VGA039Phase 3Von Willebrand Disease (VWD)HematologyOct 2028
NCT05776069VGA039Phase 1Von Willebrand DiseasesHematologyDec 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Pharmanutra VarmX MIBIO PTE. Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.